Of note, the regulation of PIK3IP1 is dependent on EZH2 methyltransferase and inhibition of EZH2 activity combined with loss of ARID1A expression is synthetically lethal [52], highlighting a potential therapeutic vulnerability through the use of EZH2 inhibitors in this tumour. This evidence concerns the gene ARID1A and neoplasm.